[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2014004738A - Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio. - Google Patents

Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio.

Info

Publication number
MX2014004738A
MX2014004738A MX2014004738A MX2014004738A MX2014004738A MX 2014004738 A MX2014004738 A MX 2014004738A MX 2014004738 A MX2014004738 A MX 2014004738A MX 2014004738 A MX2014004738 A MX 2014004738A MX 2014004738 A MX2014004738 A MX 2014004738A
Authority
MX
Mexico
Prior art keywords
phenylimidazol
sodium channel
derivatives useful
channel modulators
ethylamine derivatives
Prior art date
Application number
MX2014004738A
Other languages
English (en)
Other versions
MX337469B (es
Inventor
Sharanjeet Kaur Bagal
Mark Ian Kemp
Duncan Charles Miller
Yoshihisa Murata
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014004738(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MX2014004738A publication Critical patent/MX2014004738A/es
Publication of MX337469B publication Critical patent/MX337469B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a derivados imidazol, a su uso en medicina, a composiciones que los contienen, a procesos para su preparación y a intermediarios utilizados en tales procesos. Más particularmente, la invención se refiere a nuevos moduladores Nav1.8 imidazol de la formula (I): (Ver Fórmula) o una sal farmacéuticamente aceptable del mismo, en donde R1, R2, R3, R4 y R5 son como se definen en la descripción. Los moduladores Nav1.8 son potencialmente útiles en el tratamiento de un amplio margen de trastornos, particularmente dolor.
MX2014004738A 2011-10-26 2012-10-15 Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio. MX337469B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26
PCT/IB2012/055610 WO2013061205A2 (en) 2011-10-26 2012-10-15 Chemical compounds

Publications (2)

Publication Number Publication Date
MX2014004738A true MX2014004738A (es) 2014-08-01
MX337469B MX337469B (es) 2016-03-02

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004738A MX337469B (es) 2011-10-26 2012-10-15 Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio.

Country Status (28)

Country Link
US (1) US9079878B2 (es)
EP (1) EP2771335A2 (es)
JP (1) JP5946538B2 (es)
KR (1) KR101586966B1 (es)
CN (1) CN103906746B (es)
AP (1) AP2014007579A0 (es)
AU (1) AU2012328034B2 (es)
BR (1) BR112014009102A2 (es)
CA (1) CA2850925C (es)
CL (1) CL2014000956A1 (es)
CO (1) CO6940427A2 (es)
CR (1) CR20140185A (es)
CU (1) CU20140046A7 (es)
DO (1) DOP2014000085A (es)
EA (1) EA023375B1 (es)
EC (1) ECSP14013324A (es)
GT (1) GT201400079A (es)
HK (1) HK1198650A1 (es)
IL (1) IL232267A (es)
MD (1) MD20140037A2 (es)
MX (1) MX337469B (es)
NI (1) NI201400031A (es)
PE (1) PE20141682A1 (es)
SG (1) SG11201401032YA (es)
TN (1) TN2014000147A1 (es)
UA (1) UA109220C2 (es)
WO (1) WO2013061205A2 (es)
ZA (1) ZA201402281B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145428B2 (en) * 2011-09-14 2015-09-29 Dow Agrosciences Llc Methods and systems for forming boronic acids and intermediates thereof
RS57700B1 (sr) 2013-12-13 2018-12-31 Vertex Pharma Prolekovi piridonskih amida korisni kao modulatori kanala za natrijum
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
JP6779217B2 (ja) * 2014-10-24 2020-11-04 アヴェクタス リミテッド 細胞原形質膜を越える送達方法
US9763955B2 (en) 2015-02-19 2017-09-19 Purdue Pharma L.P. Methods and compositions for decreasing gastric emptying
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
JP7449646B2 (ja) 2015-12-30 2024-03-14 アヴェクタス リミテッド 細胞および組織への遺伝子編集タンパク質および組成物の、ベクターなしでの送達
CN110214149B (zh) * 2016-07-06 2024-05-14 沃泰克斯药物股份有限公司 用于治疗疼痛相关病症的材料和方法
AU2017292173B2 (en) 2016-07-06 2022-01-13 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
MX2019013574A (es) 2017-05-16 2019-12-18 Vertex Pharma Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio.
JP7277431B2 (ja) 2017-07-11 2023-05-19 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのカルボキサミド
JP2021512935A (ja) 2018-02-12 2021-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 疼痛を処置する方法
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
CA3164134A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
CN117858875A (zh) 2021-06-04 2024-04-09 沃泰克斯药物股份有限公司 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂
JP2024520649A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド （２ｒ，３ｓ，４ｓ，５ｒ）－４－［［３－（３，４－ジフルオロ－２－メトキシ－フェニル）－４，５－ジメチル－５－（トリフルオロメチル）テトラヒドロフラン－２－カルボニル］アミノ］ピリジン－２－カルボキサミドを含む固体剤形及び投与レジメン
EP4347584A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
EP4347583A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202408501A (zh) 2022-04-22 2024-03-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023256603A1 (en) 2022-04-22 2024-11-07 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
CN115656380A (zh) * 2022-11-09 2023-01-31 武汉海特生物创新医药研究有限公司 一种mtv对映异构体的hplc-uv检测方法
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
PL1747210T3 (pl) * 2004-05-07 2010-11-30 Warner Lambert Co Pochodne 3- lub 4-monopodstawionego fenolu i tiofenolu użyteczne jako ligandy H3
EP1809745A2 (en) * 2004-10-27 2007-07-25 Schering Corporation COMPOSITIONS AND METHODS FOR SHORT INTERFERING NUCLEIC ACID INHIBITION OF NAv1.8
CN101309909B (zh) * 2005-12-22 2012-11-14 纽朗制药有限公司 作为钙和/或钠通道调节剂的2-苯基乙基氨基衍生物
ES2357340T3 (es) 2006-10-18 2011-04-25 Pfizer Products Inc. Compuestos de biaril éter urea.
ATE461177T1 (de) 2007-03-23 2010-04-15 Icagen Inc Ionenkanal-hemmer
WO2008135826A2 (en) 2007-05-03 2008-11-13 Pfizer Limited 2 -pyridine carboxamide derivatives as sodium channel modulators
EP2155727A1 (en) * 2007-05-03 2010-02-24 Pfizer Limited N-[6-amino-5-(phenyl)pyrazin-2-yl]-isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors

Also Published As

Publication number Publication date
IL232267A (en) 2016-10-31
TN2014000147A1 (fr) 2015-09-30
JP2014530900A (ja) 2014-11-20
AU2012328034A1 (en) 2014-05-15
ECSP14013324A (es) 2014-05-31
NZ623090A (en) 2015-10-30
UA109220C2 (uk) 2015-07-27
KR20140069234A (ko) 2014-06-09
HK1198650A1 (en) 2015-05-22
SG11201401032YA (en) 2014-07-30
CN103906746A (zh) 2014-07-02
EP2771335A2 (en) 2014-09-03
WO2013061205A2 (en) 2013-05-02
IL232267A0 (en) 2014-06-30
CR20140185A (es) 2014-06-03
WO2013061205A8 (en) 2014-03-27
CU20140046A7 (es) 2014-10-02
NI201400031A (es) 2014-10-01
MX337469B (es) 2016-03-02
CA2850925C (en) 2017-01-10
AU2012328034B2 (en) 2015-04-23
BR112014009102A2 (pt) 2017-04-18
WO2013061205A3 (en) 2013-06-27
GT201400079A (es) 2015-06-02
EA023375B1 (ru) 2016-05-31
PE20141682A1 (es) 2014-11-14
MD20140037A2 (ro) 2014-08-31
CO6940427A2 (es) 2014-05-09
EA201490864A1 (ru) 2014-08-29
AP2014007579A0 (en) 2014-04-30
JP5946538B2 (ja) 2016-07-06
CN103906746B (zh) 2015-12-09
CA2850925A1 (en) 2013-05-02
CL2014000956A1 (es) 2014-07-18
DOP2014000085A (es) 2014-08-31
KR101586966B1 (ko) 2016-01-19
US20140296313A1 (en) 2014-10-02
US9079878B2 (en) 2015-07-14
ZA201402281B (en) 2015-11-25

Similar Documents

Publication Publication Date Title
MX2014004738A (es) Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio.
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
WO2012007868A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
MX2009011816A (es) Derivados de piridina.
CR20200157A (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
PH12016501028A1 (en) Prodrugs of pyridone amides useful as modulators of sodium channels
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
MX2015009591A (es) Amidas como moduladores de canales de sodio.
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
MY148948A (en) Catecholamine derivatives and prodrugs thereof
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
CA2912921C (en) Pyrazole compounds as modulators of fshr and uses thereof
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
PH12015502632A1 (en) Cxcr7 receptor modulators
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
IN2013DN02555A (es)
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators

Legal Events

Date Code Title Description
FG Grant or registration